GRAIL's Galleri Multi-Cancer Early Detection Test Advances Toward Broader Medicare Coverage

The genetic testing landscape is witnessing one of its most significant milestones as GRAIL's Galleri multi-cancer early detection (MCED) test inches closer to broad Medicare reimbursement coverage. The development represents a watershed moment for liquid biopsy technology and the broader oncology genomics sector.

Background

GRAIL's Galleri test analyzes cell-free DNA circulating in the bloodstream to detect cancer signals across more than 50 cancer types, many of which lack standard screening options today. The test uses methylation-based sequencing to identify cancer-specific patterns with high specificity, reducing false positives that have historically limited early cancer detection tools.

The company, which was acquired by Illumina before being spun off again due to regulatory pressure, has been conducting the landmark PATHFINDER study to establish clinical utility in average-risk populations.

What This Means

Centers for Medicare and Medicaid Services (CMS) coverage would be transformative for the genetic testing market. An estimated 63 million Medicare beneficiaries could become eligible for annual MCED screening if coverage is approved — creating what analysts project could be a multi-billion dollar market segment within five years.

The broader implications extend beyond GRAIL. Positive coverage decisions would validate the liquid biopsy category and accelerate investment in competing MCED programs from companies including Exact Sciences, Guardant Health, and Foundation Medicine parent Roche.

Looking Ahead

The path to reimbursement remains complex. CMS is evaluating the test under the Medicare Coverage of Innovative Technology (MCIT) pathway, and final coverage determinations will require robust real-world evidence on outcomes and cost-effectiveness.

Genetic testing companies across the industry are watching closely. A favorable ruling could unlock similar coverage pathways for pharmacogenomics, hereditary cancer panels, and other precision medicine diagnostics that currently face reimbursement barriers. The decision, expected later this year, may prove to be the most consequential regulatory moment in the genetic testing sector's recent history.